Oscar Health, Inc. (NYSE: OSCR) disclosed insider activity by Chief Accounting Officer Victoria Baltrus on March 2, 2026. Baltrus reported the sale of 4,638 shares of Class A common stock for an aggregate amount of approximately $62,102, according to a Form 4 filing with the Securities and Exchange Commission.
The transactions were executed at a weighted average price of $13.39 per share, with individual sales occurring within a range of $13.00 to $13.85.
On the same day, the filing shows Baltrus also received 17,300 shares of Class A common stock carrying a stated value of $0. Those 17,300 shares are restricted stock units (RSUs) that will vest in 12 equal quarterly installments beginning June 1, 2026.
After completing the reported sale and receiving the RSUs, Baltrus is listed as directly owning 216,112 shares of Oscar Health common stock.
Market context for the disclosure is mixed. The stock has since climbed to $15.05, moving above the weighted average price at which Baltrus sold, though shares remain down 25.6% over the prior six months.
According to InvestingPro analysis cited alongside the filing, Oscar Health appears undervalued at current levels and analysts expect the company to return to profitability this year. That commentary was presented as one of several insights available to subscribing users of the service.
Recent operating and market developments offer additional backdrop. For fourth-quarter 2025 results, Oscar Health reported an earnings per share loss of $1.24, wider than the analysts' consensus estimate of a -$0.89 EPS. Revenue for the period totaled $2.81 billion, which missed the forecast of $3.11 billion.
Despite those headline misses, the market reaction to the quarterly results was positive, with observers attributing the response potentially to the company’s forward guidance and strategic initiatives.
Separately, Raymond James revised its equity view on Oscar Health, upgrading the stock from Market Perform to Outperform and establishing a $18.00 price target. The firm cited attractive relative valuation as margins improve in the Affordable Care Act exchange market and described Oscar Health as "the best house in a tough neighborhood."
These transaction details, earnings figures and analyst positioning converge as data points for investors tracking insider behavior, valuation signals and the health-care insurer's near-term financial trajectory.